Breaks Categories: News

TuesdaySep 12, 2017 9:54 am

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Files Provisional Patent Covering Proprietary Biosynthesis Program

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its filing of a provisional patent application pertaining to the company’s biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature. Per the news release, this patent application, once converted into an international Patent Cooperation Treaty (PCT) application and pursued in key jurisdictions around the world, will offer significant commercial protections for InMed’s promising E. coli-based expression system, which enables the manufacture of any of the 90+ cannabinoid compounds found in the cannabis plant. “This novel approach to the biosynthesis of…

Continue Reading

MondaySep 11, 2017 1:11 pm

CannabisNewsBreaks – Tetra Bio-Pharma (TSX.V: TBP) (OTCQB: TBPMF) Accelerates its Cannabis-based Clinical Research Program in the Veterinary Market

Tetra Bio-Pharma (TSX.V: TBP) (OTCQB: TBPMF), a biopharmaceutical leader in cannabinoid-based drug discovery and development, is adding international expert Dr. Louis-Philippe de Lorimier, a board certified veterinary oncologist, to its clinical advisory board for the veterinary market. In a news release, Dr. Guy Chamberland, chief scientific officer of Tetra Bio-Pharma, said, "We are leveraging our current R&D work in humans to accelerate the development of the first cannabinoid-based drug for pets in the cancer-associated supportive therapy market, including pain. This market is underserved and patients and their owner are waiting for alternatives that are safer, more tolerable and more efficacious.”…

Continue Reading

MondaySep 11, 2017 12:20 pm

CannabisNewsBreaks – Terra Tech Corp. (TRTC) Files Provisional Patent Application for Cannabis-Infused Rolling Papers

Terra Tech Corp. (OTCQX: TRTC), a vertically integrated, cannabis-focused agriculture company, has filed a patent application with the U.S. Patent and Trademark Office for innovative cannabis-infused rolling papers. Expected to launch in 2018, the inventive rolling papers will be the latest addition to the company’s portfolio of IVXX™ branded premium cannabis products, which includes flowers, concentrates, custom-rolled joints and edibles. As with all its products, the rolling papers will be free of toxic pesticides, harmful molds and chemical residues, the company states. In the news release, Derek Peterson, CEO of Terra Tech, said, “Infusing rolling papers with cannabis can enhance…

Continue Reading

ThursdaySep 07, 2017 1:09 pm

CannabisNewsBreaks – Organigram (TSX.V: OGI) (OTCQB: OGRMF) Enters into MOU for Microwave Assisted Extraction Technique Development

Organigram Holdings Inc. (TSX.V: OGI) (OTCQB: OGRMF) will jointly develop an industry leading method of microwave extraction of cannabinoid extracts from marijuana plants with the New Brunswick Innovation Research Chair in Medical Technologies (NBIRC), an initiative of the New Brunswick Innovation Fund (NBIF), it was announced Wednesday. A memorandum of understanding between Organigram Holdings Inc. and NBIRC details the project which will focus on developing a more efficient manner of extracting cannabinoids for use in extracts and edibles. The project will be led by Dr. J. R. Jocelyn Paré, holder of the NBIRC, the inventor of various Microwave-Assisted Processes forming…

Continue Reading

ThursdaySep 07, 2017 9:31 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Names Barry Fishman as New CEO

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced the appointment of Barry Fishman as its new chief executive officer, effective October 1, 2017. Fishman brings nearly two decades of experience as a business leader to the ABcann team, having most recently served as CEO of international specialty pharmaceutical company Merus Labs. Under his leadership, Merus’s sales and EBITDA grew at a CAGR of greater than 50 percent, leading to the company’s acquisition by Norgine B.V. in July 2017 for total considerations of roughly $342 million. “Barry's proven experience as a CEO of complex, highly-regulated organizations with international operations…

Continue Reading

ThursdayAug 31, 2017 9:20 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Clinical Study of High Absorption TurboCBD™ Product

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s TurboCBD™ product. The study, which aims to evaluate the effects of TurboCBD™ on both cardiovascular health and cognitive function, will have a double-blind and placebo controlled cross-over design measuring effects after a single dose, as well as seven days of daily dosing, in 24 volunteers. “Lexaria is proud to be advancing our collective knowledge of the benefits of CBD specifically showcasing the benefits of…

Continue Reading

TuesdayAug 29, 2017 9:31 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Scheduled to Attend Two Cannabis Conferences in September

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced its plans to attend two cannabis investment conferences in September. The first, the Investorshub International Cannabis Conference, will be held at the JW Marriott in downtown Los Angeles on September 1-2. The second, the Institutional Capital & Cannabis Conference (East), is scheduled to take place on September 7-8 in Miami Beach. This morning’s news release also included an update on the company’s financing activities. Notably, Lexaria has received and executed a notice of conversion related to certain…

Continue Reading

MondayAug 28, 2017 9:15 am

CannabisNewsBreaks – ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Announces Release of High Level CBD Product

ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced the release of one of Canada’s highest legal CBD:THC ratio products by wholly-owned subsidiary ABcann Medicinals Inc. CBD-Med has a ratio of 27.6:1 (18.5% CBD to 0.67% THC), making it one of Canada’s highest CBD products under Health Canada regulations. “The development of these products is in line with ABcann's corporate strategy as a premium product provider of organic, pesticide free cannabis,” Ken Clement, executive chairman of ABcann, stated in the news release. “As the Company continues to scale production capacity, our product line will expand as we strive to…

Continue Reading

ThursdayAug 10, 2017 9:32 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) CEO Discusses Company’s Progress in Interview

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced that its chief executive officer, Chris Bunka, was featured in a recent interview on the Uptick Network Stock Day Radio Show. Bunka leveraged the platform to discuss Lexaria’s overall accomplishments in the past three months, as well as the company’s expectations for profitability moving forward. He notes that ongoing research and development programs could open both the NSAID and Nicotine markets to Lexaria, providing an opportunity to significantly increase corporate revenues and facilitate further expansion. “In the…

Continue Reading

WednesdayAug 02, 2017 3:23 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Spotlighted by Technical420

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, including cannabinoids, was recently spotlighted in an article on Technical420.com. The publication highlighted, in detail, several of the company’s key developments and growth catalysts. “During the last few months, Lexaria has improved its fundamental story through the following developments: 1) The company applied for a new patent from the U.S., 2) Lexaria has advanced its agreements and launched new businesses, 3) Expands its Reach into Asia, 4) Focused on R&D with major organizations, and 5) The company’s cash position has…

Continue Reading